Bloom Science

Bloom Science has announced positive topline data from a Phase I clinical trial of BL-001, a potential first-in-class therapeutic the company is developing for Dravet syndrome and amyotrophic lateral sclerosis (ALS). In the trial, BL-001 demonstrated a favourable safety profile and was well tolerated with no serious adverse events (SAEs) across all four dose cohorts. […]

Bloom Science has completed enrolment of healthy adult participants as part of its Phase I clinical trial into BL-001 for Dravet syndrome, a rare paediatric epilepsy. BL-001 is an orally administered Live Biotherapeutic Product reverse translated from the positive clinical outcomes associated with the Ketogenic Diet in treating refractory epilepsy. The Phase I study of […]